Academic institutions grant commercial license for CRISPR-based SHERLOCK diagnostic technology in developed world
Rights are protected for broad use in developing world and for public health needs.
CRISPR team harnesses new Cas12b enzyme for use in eukaryotic cells, adding to the CRISPR toolbox.
Enzyme can target almost half of the genome’s “ZIP codes” and could enable editing of many more disease-specific mutations.
Whitehead team deploys CRISPR tools to better understand and uncover ways of improving methotrexate, a popular chemotherapy drug.
Study reveals why people with the APOE4 gene have higher risk of the disease.
With SHERLOCK, a strip of paper can now indicate presence of pathogens, tumor DNA, or any genetic signature of interest.
“REPAIR” system edits RNA, rather than DNA; has potential to treat diseases without permanently affecting the genome.
Biological engineers identify genes that protect against protein linked to Parkinson’s disease.
MIT associate professor and member of the Broad Institute and McGovern Institute recognized for commitment to invention, collaboration, and mentorship.